Compare EDIT & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | ARL |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 246.8M |
| IPO Year | 2016 | 1999 |
| Metric | EDIT | ARL |
|---|---|---|
| Price | $2.66 | $14.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.92 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 1.7K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.50 | ★ 206.59 |
| EPS | N/A | ★ 0.97 |
| Revenue | $31,937,000.00 | ★ $50,014,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.18 |
| Revenue Growth | ★ 132.64 | 5.70 |
| 52 Week Low | $0.91 | $10.57 |
| 52 Week High | $4.54 | $20.00 |
| Indicator | EDIT | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 35.67 |
| Support Level | $2.42 | $13.66 |
| Resistance Level | $2.76 | $16.76 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 87.10 | 16.53 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.